Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

$345.24
+5.51 (+1.62 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$342.16
Now: $345.24
$347.27
50-Day Range
$313.55
MA: $332.27
$343.97
52-Week Range
$220.05
Now: $345.24
$347.27
Volume383,034 shs
Average Volume183,638 shs
Market Capitalization$10.29 billion
P/E Ratio59.12
Dividend YieldN/A
Beta1.18
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$6.0251 per share
Book Value$134.91 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$10.29 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories announced that its Board of Directors has approved a share buyback program on Wednesday, November 29th 2017, which allows the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings results on Thursday, August, 1st. The medical research company reported $1.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.39 by $0.18. The medical research company earned $572.60 million during the quarter, compared to analysts' expectations of $564.88 million. Bio-Rad Laboratories had a net margin of 39.32% and a return on equity of 3.92%. The company's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.64 EPS. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Bio-Rad Laboratories.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.38171336-2.393163905 billion, compared to the consensus revenue estimate of $2.35 billion.

What price target have analysts set for BIO?

4 brokerages have issued twelve-month price objectives for Bio-Rad Laboratories' stock. Their forecasts range from $375.00 to $420.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $393.75 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:
  • 1. According to Zacks Investment Research, "Over the past year, Bio-Rad has outperformed its industry. We are encouraged with the year-over-year rise in earnings in the last-reported quarter. Constant currency sales growth at the Clinical Diagnostics segment was impressive. The company also saw strong growth in the Life Science segment and cell biology, droplet Digital PCR, gene expression and antibody product lines. Further, solid revenue growth in geographies like Americas and Asia Pacific buoys optimism. We are also upbeat about the company’s receipt of FDA approval for the QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit.  However, challenges associated with the implementation of the global ERP system raise concerns. Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates." (5/1/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "We see substantial hidden value in BIO’s droplet digital PCR (ddPCR) franchise that is under-appreciated by investors." (9/24/2018)

Has Bio-Rad Laboratories been receiving favorable news coverage?

News coverage about BIO stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Bio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in August. As of August 31st, there was short interest totalling 552,800 shares, an increase of 14.7% from the July 31st total of 482,100 shares. Based on an average daily trading volume, of 181,400 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.6% of the shares of the company are short sold. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), Dynavax Technologies (DVAX), Celgene (CELG), ImmunoGen (IMGN), Array Biopharma (ARRY) and Exelixis (EXEL).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.55%), BlackRock Inc. (6.55%), Vanguard Group Inc. (6.39%), Atlanta Capital Management Co. L L C (2.54%), Russell Investments Group Ltd. (1.38%) and UBS Asset Management Americas Inc. (1.33%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, AQR Capital Management LLC, Cibc World Markets Corp, Hoplite Capital Management L.P., BNP Paribas Arbitrage SA, Canada Pension Plan Investment Board, Citadel Advisors LLC and Fort Washington Investment Advisors Inc. OH. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Insider Buying and Selling for Bio-Rad Laboratories.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Invesco Ltd., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Nuveen Asset Management LLC, Prudential Financial Inc., WINTON GROUP Ltd and Tamarack Advisers LP. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $345.24.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $10.29 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.View Additional Information About Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel